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Rapport de synthèse 
les concentrations sériques d'hormone antimüllérienne restent 
stables pendant le cycle menstruel et après administration orale ou 
vaginale de stéroïdes sexuels de synthèse 
Objectif de l'étude : étudier si l'administration orale ou vaginale 
d'hormones contraceptives influence les concentrations sériques 
d'hormone antimüllérienne (AMH). 
Design : essai prospectif chez des femmes recrutées par annonce. Les 
femmes désireuses d'avoir une contraception ont été randomisées entre 
une contraception orale et une contraception vaginale. Celles qui ne 
souhaitaient pas de contraception ont été incluses dans le groupe 
témoin. 
Cadre de l'étude : unité de médecine de la reproduction d'un hôpital 
universitaire. 
Patientes : vingt-quatre jeunes femmes en bonne santé avec des cycles 
menstruels réguliers qui n'avaient pas utilisé de contraception hormonale 
pendant les trois mois précédant l'étude. 
Intervention : contraception orale ou vaginale du 5ème au 25ème jour du 
cycle menstruel dans les groupes contraception versus pas de 
contraception dans le groupe témoin. 
Mesure d'issue : variations inter et intra-cycle des concentrations 
sériques d'AMH dans les trois groupes: groupe témoin en cycle 
spontané et groupes sous contraception oestroprogestative orale ou 
vaginale. 
Résultats: les fluctuations d'AMH observées pendant le cycle menstruel 
(variations intra-cycle) restent dans les valeurs des variations entre deux 
cycles (variations inter-cycles) tant chez les femmes en cycle spontané 
que chez les femmes sous contraception orale ou vaginale. 
Conclusions : nos résultats confirment que les concentrations sériques 
d'AMH restent stables pendant le cycle menstruel et indiquent qu'elles 
ne sont pas influencées par l'administration exogène de stéroïdes 
sexuels contraceptifs, que ce soit par voie orale ou vaginale. 
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Objective: To investigate whether the oral or vaginal administration of contraceptive hormones might affect anti-
müllerian hormone (AMH) levels. 
Design: Prospective trial with women recruited by adve1tisement. Women who wished contraception were ran-
domized between oral or vaginal estroprogestative contraception, and those who did not choose contraception 
were included in the control group. 
Setting: Fertility clinic of a te1tiary university hospital. 
Palient(s): Twenty-four young, healthy volunteer women with regular cycles who had received no hormonal con-
traception for at least 3 months before the study. 
lntervenlion(s): Oral or vaginal estroprogestative contraception from day 5 to 25 of a menstrual cycle versus no 
contraception. 
Main Outcome Measure(s): Intercycle and intracycle variations of serum AMH levels in normally ovulating vol-
unteers and following the initiation of oral or vaginal estroprogestative contraception. 
Result(s): Fluctuations of AMH levels observed during the menstiual cycle remained within cycle-to-cycle var-
iability in cycling controls and in women receiving oral or vaginal contraception. 
Conclusion(s): Our findings confirm that AMH levels remain steady during the menstiual cycle, indicating that 
they are unaffected by exogenous sex steroids used for contraception whether administered orally or vaginally. 
(Fertil Steril® 2007; Il: 11111-11. ©2007 by American Society for Reproductive Medicine.) 
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Antimüllerian hormone (AMH), a member of the transform-
ing growth factors superfamily, is solely synthesized in gen-
ital organs. Known for over five decades for its role in the 
organogenesis of internal sex organs, AMH has recently 
been rediscovered when ultrasensitive assays revealed that 
it is synthesized by adult gonads in both sexes. In females, 
AMH is produced by preantral and small antral follicles 
and may serve as a paracrine regulator of early follicular 
growth (1). Mounting evidence indicates that AMH levels, 
which reflect the size of the cohort of recruitable follicles, 
also predict the magnitude of the ovarian response to con-
trolled ovarian hyperstimulation (COH). As the number of 
preantral and antral follicles directly reftects the size of the 
cohort of primordial follicles, AMH levels have been pro-
posed as a marker of ovarian reserve. 
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Several studies have supported the concept that AMH 
levels remain constant throughout the menstrual cycle in 
the adult female (2, 3), in pregnancy, and in the puerperium 
(4). Hence, AMH levels appear to be independent of gonad-
otropin levels. The stability of AMH levels throughout the 
various steps of reproductive physiology constitutes a definite 
practical advantage for using AMH measurements when in-
vestigating and managing infertility. The stability of AMH 
makes it the only marker of ovarian reserve that eau be mea-
sured indiscrirninately during the menstrual cycle for fertility 
workups. Yet, in our practice, incidental findings of low 
AMH levels encountered in women receiving contraceptive 
hormones vaginally led us to query whether AMH levels 
might be affected by exogenous estroprogestative hormones. 
Our randomized trial studied the effect of oral or vaginal ad-
ministration of contraceptive hormones on AMH levels in 
women who previously had ovulated regularly. 
MATERIALS AND METHODS 
The study protocol was reviewed and accepted by the institu-
tional review board. Written, informed consent was obtained 
from each woman participating in the study. We recruited 24 
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healthy volunteers to participate in this trial. All volunteers 
were regularly cycling women, with menstrual cycles lasting 
from 25 to 35 days, who had received no hormonal contracep-
tion for at least 3 consecutive months before recruitment. The 
study took place between March and September 2006 at the 
infertility clinic of the Gene va University Hospital. The study 
protocol excluded women whose history revealed irregular 
cycles and/or was suggestive of polycystic ovary syndrome 
(PCOS) and/or constituted a contraindication to hormonal 
contraception (high blood pressure, family history of throm-
bosis, or sudden unexplained death). 
The women were recruited by advertisement and were first 
asked whether they were interested in contraception. Those 
who wished contraception were randomized between two 
contraceptive methods. The women who did not want any 
contraception were included in the control group (group 1). 
The 14 women accepted hormonal contraception were ran-
domized to receive either 0.02 mg of ethinylestradiol (EE) 
plus 0.15 mg of desogestrel (DSG) orally (Mercilon; Orga-
non Pharmaceuticals, Oss, the Netherlands) (group 2) or 
0.015 mg of EE and 0.12 mg of etonogestrel, the active me-
tabolite of DSG, through a vaginal ring (Nuvaring; Organon) 
(group 3). The hormones were administered from day 5 to 25 
of the menstrual cycle. Group randomization relied on opa-
que, sealed envelopes. Ten women without contraception 
were included in the control group. 
Blood samples for AMH measurement were taken on four 
occasions: days 2 to 4 (intercycle 1), days 16 to 18, days 23 to 
25 of the first menstrual cycle, and days 2 to 4 of the next 
menstrual cycle (intercycle 2). 
Serum AMH was measured by enzyme-linked immuno-
sorbent assay (ELISA) using the AMH/müllerian-inhibiting 
substance (MIS) ELISA kit (Immunotech-Beckman, Mar-
seilles, France). The detection li mit of the assay was 0.1 
ng/mL; the interassay coefficients of variation were 9.6% 
for a serum AMH concentration of 3.5 ng/mL and 13.7% 
for a serum AMH concentration of 9 ng/mL. The intra-assay 
coefficient of variation was 4.1 % for a serum AMH concen-
tration >0.4 ng/mL. These coefficients of variation served as 
a reference for judging AMH variations occurring during the 
menstrual or hormone contraception cycles. 
On days 2 to 4 of the first cycle, an ultrasound with antral 
follicular count (AFC) was performed and serum follicle-
stimulating hormone (FSH) levels were measured. Serum 
FSH levels were also measured on days 2 to 4 of the following 
cycle. 
Statistical analysis was performed using SPSS software 
version 14.0 (SPSS, Inc., Chicago, IL). The power analysis 
for repeated measures was performed using Acluster Version 
2.0 (World Health Organization, Geneva, Switzerland). 
Spearman's correlation test was used to analyze the relation-
ships among AFC, age, and the AMH and FSH levels on days 
2 to 4 of both cycles. An analysis of variance (ANOVA) for 
repeated measures was used to analyze AMH fluctuations 
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occurring within the menstrual cycle in the control group 
(group 1) and after administering contraceptive hormones 
in groups 2 and 3. Differences in AMH values among the 
three groups were tested using ANOVA. Data are expressed 
as mean ± standard deviation (SD). In all analyses, P<.05 
was considered statistically significant. 
RESULTS 
All three study groups had comparable characteristics, with 
overall mean of 24.1 years (SD ± 3.5) for age, 21.5 kg/m2 
(SD ± 2.1) for body mass index, 29.3 days (SD ± 2.7) for cy-
cle length, and 13 years (SD ± 1.2) for age at menarche (Ta-
ble 1). None of the differences among the groups reached 
statistical significance. 
The FSH levels were measured in all of the women on days 
2 to 4 of both studied cycles. All of the women had FSH levels 
<10 IU/L in both cycles, with an overall mean of 5.34 (SD ± 
1.58) IU/L and 5.32 (SD ± 2.23) IU/L in the first and second 
cycles, respectively. The AFC, evaluated on days 2 to 4 of the 
first cycle, was normal in all of the women, ranging from 17 
to 41 follicles and with an overall mean of 28.5 follicles (SD 
± 7). There were no differences in FSH levels or AFC among 
the three groups. The FSH and AMH measures showed a sta-
tistically significant inverse correlation on days 2 to 4 ofboth 
cycles with Spearman's correlation coefficients of -0.57 and 
-0.53 for the first and second cycles, respectively. There was 
no correlation of AFC with age or the baseline AMH or FSH 
levels, with Spearman's correlation coefficients of 0.15, 
-0.01, and -0.3, respectively. 
In the control group, mean AMH levels on days 2 to 4 were 
4.4 (SD ± 1.2) and 4.2 (SD ± 1.4) ng/mL for the first and sec-
ond cycles, respectively. Mean intracycle levels on days 16 to 
18 and 23 to 25 were 4.2 (SD ± 1.7) and 4.3 (SD ± 2.29) 
ng/mL, respectively. In women who started oral contraception 
on day 5 (group 2), the mean AMH levels on days 2 to 4 were 
5.0 (SD ± 2.0) and 6.2 (SD ± 3.0) ng/mL for the first and sec-
ond cycles, respectively. The mean intracycle levels on days 
16 to 18 and 23 to 25 were 5.2 (SD ± 2.2) and 5.4 (SD ± 
2.3) ng/mL, respectively. In the women who started vaginal 
contraception on day 5 (group 3), the mean AMH levels on 
days 2 to 4 were 4.9 (SD ± 3.3) and 5.5 (SD ± 4.1) ng/mL 
for the first and second cycles, respectively. The mean intra-
cycle levels on days 16 to 18 and 23 to 25 were 4.5 (SD ± 
2.8) and 4.8 (SD ± 3.1) ng/mL, respectively (Fig. 1). 
The longitudinal changes of AMH levels in individual 
women in the three groups are described in Figure 2. 
In the control group, the intercycle variability of individual 
AMH values was 28.5 ± 26.4% (group 1). This did not differ 
in a statistically significant fashion from the values of 26.8 ± 
30.8% and 23.8 ± 18.8% observed for intercycle variability 
of individual values following oral and vaginal contraception 
(groups 2 and 3), respectively. 
In all cases, the changes in AMH values measured during 
the menstrual cycle and while receiving oral and vaginal 
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! 1: 
Patient characteristics in the three groups (mean and standard deviation). 
Contrai group Contraceptive pill group Contraceptive ring group Total 
ofwomen 10 7 7 24 
Age (years) 24.3 (4.9) 24.6 (1.3) 23.3 (2.7) 24.1 (3.5) 
Cycle length (days) 28.4 (1.6) 30.3 (2.4) 29.7 (4.0) 29.3 (2.7) 
Body mass index (kg/m2) 21.3 (2.1) 21.4 (1.2) 21.9 (3.0) 21.5 (2.1) 
Number of pregnancies 0.2 (0.4) 0 0.1 (0.4) 0.13 (0.3) 
Number of deliveries 0 0 0 0 
Antral follicular count 30.7 (8.2) 27.7 (5.1) 26.3 (6.8) 28.5 
FSH day 2-4 (cycle 1) 5.5 (1.9) 
FSH day 2-4 (cycle 2) 5.6 (2.3) 
contraception remained well within the intercycle variability 
observed in untreated controls. None of the intracycle varia-
tions within each group and compared among the three 
groups reached statistical significance. 
The intraclass correlation coefficients were 0.72 between 
groups 1 and 2, 0.85 between groups 1 and 3, and 0.89 be-
tween groups 2 and 3. Our study had enough participants to 
detect differences corresponding to ±1.5 SD of AMH levels 
(3 ng/mL), a clinically meaningful difference. In this case the 
study power varies between 77% and 90% for intraclass cor-
relation coefficients between 0.9 and 0.7. Our study is under-
powered, however, for detecting differences corresponding to 
±1 SD of AMH levels (2 ng/mL), with a power in the latter 
case ranging between 44% and 55% for intraclass correlation 
coefficients between 0.9 and 0.7. 
DISCUSSION 
Our study confirms prior reports indicating that AMH levels 
do not ftuctuate significantly during the menstrual cycle. In 
5.5 (1.2) 5.0 (1.5) 5.3 
4.8 (2.8) 5.3 (1.9) 5.3 
our study, variations in AMH levels seen during the menstrual 
cycle fell well within the intercycle variability observed in 
our participants. Our results also suggest that hormonal con-
traception, whether administered orally or vaginally, has no 
effect on AMH levels. 
The mean AMH levels tended to be higher in group 2, who 
were receiving oral contraception, intermediate in the group 
3, who were receiving vaginal contraception, and lowest in 
the controls. However, these differences among the three 
groups had existed before treatment was initiated and were 
not statistically significant. As illustrated in Figure 2, longi-
tudinal changes of AMH levels observed in each individual 
were comparable among the three groups. 
Our study had enough power to detect a clinically mean-
ingful difference of3 ng/mL, equivalent to ± 1.5 SD of the over-
all mean of AMH levels. Further studies are needed to detect 
possible fluctuations of AMH levels of smaller amplitude taking 
place during the menstrual cycle or as a result of oral or vaginal 
contraception. Such smaller differences might be informative 
Antimüllerian hormone (AMH) fluctuations in the three groups. Serum AMH levels measured at four different times 
(mean ± SD) in the three groups. The AMH levels remained stable in cycling contrais (group 1, open bars, n = 10) 
and in women receiving hormone contraception administered orally (group 2, diagonal hatching, n = 7) or 
vaginally (group 3, horizontal hatching, n = 7). 
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Longitudinal changes of antimüllerian hormone (AMH) levels in individuals. Each patient's AMH level on days 2 to 
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on possible regulatory mechanisms affecting circulating AMH 
levels, but they would be of minor clinical meaningfulness 
when interpreting AMH levels for assessing ovarian reserve. 
All study participants were normally cycling women in 
their twenties with no contraception for at least 3 months be-
fore the study, no signs or history of PCOS, and a normal ovar-
ian reserve as assessed by FSH levels and AFC on days 2 to 4. 
Randomization only concerned women who desired contra-
ception; it was considered ethically undesirable to randomize 
between contraception and no contraception because of the 
risk of undesired pregnancies. Otherwise, the three groups 
had comparable characteristics, as illustrated in Table 1, and 
we believe that this limitation in the study design was unlikely 
to affect our results and conclusions. Our findings show a wide 
variation in follicle numbers in women of similar age and no 
correlation of AFC with AMH and FSH levels or age. 
These results seem surprising at first, but we realize that 
there is scarce information on AFC in cycling women in their 
twenties who have no history of infertility or PCOS. Two 
studies that reported high AFC values with wide variations 
in women of this age group are supportive of our findings. 
Ruess et al. (5) reported a mean AFC of 36.6 (SD ± 12.1) 
with a range of 23 to 63 in 10 women in their early twenties. 
A study by Scheffer et al. (6) reported a high variation in AFC 
within each age group. A recently published study by Somun-
kiran et al. (7) described a positive correlation between AFC 
and baseline AMH levels in 30 women with PCOS. Yet the 
same correlation was absent in 15 normally cycling controls 
who were matched for age and body mass index. 
Our findings are comparable with those reported by La 
Marca et al. (3) who found stable AMH levels measured ev-
ery other day in 12 cycling women with a mean age of 23 ± 3 
years. Another study by Hehenkamp et al. (2) conducted in 44 
women with proven fertility, aged 25 to 46 years (mean age: 
38 years) also concluded that AMH does not follow a cyclic 
pattern and is independent of hormonal fluctuations in the hy-
pothalamo-ovarian crosstalk system. 
The only data suggesting a small but statistically signifi-
cant periovulatory rise in AMH levels were reported by 
Cook et al. (8). However, these investigators concluded that 
the small fluctuations observed were probably of no clinical 
relevance and did not suggest AMH dependency on the hypo-
thalamo-ovarian feedback mechanism. 
Our study extends these findings by indicating that AMH 
levels also are unaffected by exogenous estrogens and pro-
gestins used for contraception, whether administered orally 
or vaginally. This information is of great practical value as 
it indicates that AMH measurement retains its entire value 
as a predictor of ovarian reserve even in women taking hor-
monal contraception. 
Our results are consistent with the concept that AMH re-
flects the continuous noncyclic growth of small follicles in 
the ovary (1). Schematically, two steps are recognized in fol-
licular growth depending on whether it is dependent of gonad-
Fertility and Sterility® 
otropins. The initial recruitment and growth of primordial 
follicles, which appears relatively gonadotropin independent 
is referred as the noncyclic recruitment phase. The second or 
cyclic phase leads to the recruitment, selection, and matura-
tion of the ovulatory follicles under the influence of FSH 
and LH. Weenen and al. (1) studied AMH expression patterns 
in human granulosacells at different stages offollicular devel-
opment. AMH was absent in primordial follicles and reached 
its highest expression levels in preantral and small antral fol-
licles, disappearing in larger follicles undergoing recruitment 
and in atretic follicles. These results strengthen the hypothesis 
that AMH, produced by the pool of growing follicles, acts as 
a paracrine feedback signal inhibiting initial recruitment of 
primordial follicles. Thus, it is logical to assume that AMH 
levels do not fluctuate during the menstrual cycle and should 
therefore not be affected by hormonal changes such as those 
induced by pregnancy or exogenous hormonal administration, 
including hormonal contraception. 
La Marca et al. (4) evaluated AMH levels during gestation 
and the early puerperium and studied the relationship be-
tween FSH and AMH levels during pregnancy. The values 
of AMH remained stable during gestation, suggesting that 
early follicular development, and therefore AMH production, 
continues during pregnancy without being affected by de-
creasing FSH levels. 
Oral or vaginal administration of contraceptive hormones 
profoundly affects gonadotropin levels and in turn ovarian 
function. Our results showed no differences in AMH levels af-
ter regularly cycling women initiated oral or vaginal hormonal 
contraception. This further supports the concept that AMH 
levels are not affected by changes in gonadotropins induced 
by exogenous estroprogestative hormones and that the noncy-
clic recruitment of follicles is not altered during hormonal 
contraception. One limitation of our study, however, is its du-
ration. For methodological reasons, we selected women who 
had not been on hormone contraception for at least 3 months 
and studied the impact of 1 month of treatment. 
After submission of our study, Somunkiran et al. (7) re-
ported on the effects of hormonal contraception (35 µg of 
EE and 2 mg of cyproterone acetate) on AMH levels in 30 
women with PCOS and in 15 normally cycling controls 
matched for age and body mass index, and found no changes 
in either group over a period of 6 months. The investigators 
concluded that AMH can be used as a diagnostic marker of 
PCOS in patients taking contraception. Our study confirms 
that conclusion and extends it to vaginally administered hor-
monal contraception. 
Our observation that contraceptive hormones have no effect 
on AMH levels further supports the concept that AMH is not 
affected by FSH levels, at least not within the range of changes 
commonly encountered in reproductive physiology. 
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